Chairside risk assessment test rapidly detects higher levels of Streptoccocus muta

Feb. 6, 2009
Saliva Check Mutans can monitor the end result of disease, cavities and the causative factors of the disease.

GC America has announced a new addition to its preventive line of products with Saliva Check Mutans Kit.

The kit is a chairside risk assessment test for rapid detection of higher levels of Streptoccocus mutans (S.mutans).

Streptococcus mutans is known to be the prime etiologic agent of human dental caries. A patient, who has more than 500,000CFU/mL of S.mutans in saliva, has a high caries risk.

Saliva Check Mutans aids in the management of dental caries throughout the patient's life. It can monitor the end result of disease, cavities and the causative factors of the disease.

In addition, this chairside test, can educate and motivate patients to maintain a healthy oral environment. It simplifies and visually communicates the essential concepts of tooth decay.

Saliva Check Mutans will be available March 1, 2009. from GC authorized dental dealers.

In addition to MI Paste and MI Paste Plus, GC America has an array of risk- assessment products to offer the dental practice and patients. GC Plaque-Indicator Kit, Saliva-Check Buffer Kit and now Saliva Check Mutans help to bring awareness of the importance of saliva.

If you would like more information on GC America's products, visit GC America.

To read more about GC America, go to GC America.

To comment on this product, go to PennWell Dental Community site.